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ns.org/licenses/by-nc-nd/4.0/)recommends that antimuscarinics and mirabegron, a b3-
adrenoreceptor, as ﬁrst-line pharmacotherapy options for
OAB,3 there is evidence that in clinical practice mirabe-
gron may only be offered after treatment failure with anti-
muscarinics.4 Furthermore, it has been recently suggested
that onabotulinumtoxinA, currently a third-line treatment
option, could offer beneﬁts to patients with OAB prior to
treatment with antimuscarinics or mirabegron.5
Although several clinical trials have directly compared
mirabegron to antimuscarinics,6-8 there have been no
head-to-head comparisons of mirabegron versus onabotu-
linumtoxinA.
In the absence of direct comparisons, network-meta
analyses (NMAs) have been conducted comparing the
efﬁcacy of mirabegron and onabotulinumtoxinA for the
treatment of OAB9,10; however, these have not investi-
gated the relative safety of onabotulinumtoxinA versus
mirabegron, nor have they appropriately accounted for
the inherent differences in trial patient populations. Mira-
begron (and antimuscarinic) trials have typically included
a mixed patient population of treatment-na€ıve and treat-
ment-experienced patients, while onabotulinumtoxinA
trials have included treatment-experienced patients with
a longer disease history and greater symptom severity.
Heterogeneity in patient populations may lead to1https://doi.org/10.1016/j.urology.2019.02.005
0090-4295
important variability in treatment prognosis. Furthermore,
with the availability of new evidence from clinical trials,
results from previous NMAs may have become out-
dated.11-17
The NMA presented in this paper builds upon the
existing literature. The primary aim of this study was to
compare the efﬁcacy of mirabegron 50 mg and onabotuli-
numtoxinA in the management of treatment-experienced
patients with OAB. Additionally, this study aimed to
compare the safety proﬁles of mirabegron and onabotuli-
numtoxinA in this population.METHODS
Evidence Identification
Search Strategy. To inform the NMA, a comprehensive sys-
tematic search of the published literature was conducted
through a review of the Medline and Medline in-progress
(OVID SP), EMBASE (OVID SP) (which includes the
Cochrane Central Register of Controlled Trials [CENTRAL]),
and PubMed databases. The search was not limited by country
or geographic region; however, it was limited to English lan-
guage publications. The study period was from January 1, 2005
to October 19, 2016, deﬁned to capture all relevant studies
including mirabegron or onabotulinumtoxinA, while ensuring
a contemporary patient population for publications focusing on
antimuscarinics. The search was guided by the population,
interventions and/or comparators, outcomes, study design crite-
ria (Supplementary Table 1). Studies eligible for inclusion were
among adults (≥18 years) with OAB who have received at least
one prior OAB pharmacotherapy (to be eligible for inclusion,
at least 80% of the patient population described in the study
was required to be treatment-experienced, or have endpoints
reported for the subgroup of treatment-experienced patients)
and included one or more treatments of interest. Although the
search was not speciﬁc to the US, only treatments approved for
use in the US and placebo were eligible. As such, mirabegron
(25 or 50 mg), onabotulinumtoxinA (100 U), and any of the
antimuscarinics most commonly used in the US to treat OAB,
including darifenacin (7.5, 15 mg), fesoterodine (4, 8 mg), oxy-
butynin (transdermal patch: 3.9 mg; gel: 100 mg; syrup: 5 mg;
tablet: 5, 10, 15 mg), solifenacin (5, 10 mg), tolterodine (1, 2, 4
mg) or trospium chloride (60 mg) or to no treatment and/or pla-
cebo were included. An a priori decision was made to include
studies that compared two or more antimuscarinics or compared
an antimuscarinic to a placebo, as they had the potential of
contributing intermediate information to the network of evi-
dence, for the comparison of mirabegron versus onabotulinum-
toxinA, even though antimuscarinics themselves were not
comparators of interest. Because such studies were included in a
systematic and comprehensive way, they allowed for a more
complete evidence network, with additional information
regarding antimuscarinic efﬁcacy and safety, and were not
anticipated to introduce bias to comparisons of interest. Net-
works based on direct versus indirect evidence were also com-
pared to assess any potential discrepancies. To be considered
for inclusion, eligible studies were required to report on at least
one of the efﬁcacy or safety endpoints listed in Supplementary
Table 1. Studies including patients with OAB and urinary
incontinence with a known cause (eg surgery, pregnancy,
benign prostatic hyperplasia, bladder outlet obstruction, spinal2cord injury) or with any of the following conditions: neurogenic
OAB, stress urinary incontinence, bladder oversensitivity, or
bladder hypersensitivity were excluded. Studies that included
mixed populations for which results were not reported sepa-
rately for idiopathic OAB subgroup, and studies that did not
present data in such a way that endpoints for a treatment-expe-
rienced population (of at least 80%) could be identiﬁed
were also excluded. Lastly, cross over studies for which results
were not reported before cross over occurred were not included.Study Identiﬁcation and Selection. Two reviewers indepen-
dently reviewed identiﬁed abstracts against the study’s inclusion
and/or exclusion criteria; abstracts included at this stage were
subsequently reviewed in full-text. Final assessments by the
2 reviewers were compared for reconciliation. Any discrepancies
between the studies selected for inclusion by the 2 researchers
were arbitrated by a third reviewer. When the study did not
meet either the a priori inclusion and/or exclusion criteria, rea-
sons for ineligibility were recorded and a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses ﬂowchart
was generated.Sub-analysis of Initially Excluded Mirabegron Studies. The
evidence generated by the systematic search was supplemented
by post-hoc analyses conducted on the subset of treatment-expe-
rienced patients from mirabegron studies that were initially
excluded due to an insufﬁcient proportion of treatment-
experienced patients. Results from the post-hoc analyses repre-
sent a subset of the overall evidence base; individual patient-
data were only available from mirabegron studies such that a
post-hoc analysis of treatment-experienced patients was not
feasible for other comparators. The inclusion of unpublished
results where available strengthens the evidence base and is in
alignment with the Cochrane Handbook for Systematic Reviews
of Interventions.18Data Extraction and Quality Assessment. Double data extrac-
tion into a customized Microsoft Excel data extraction work-
book was performed for all efﬁcacy and safety endpoints data of
interest from the eligible studies. All other details of interest
were extracted by one reviewer and quality checked by a second
reviewer. Any discrepancies were resolved through discussion to
achieve consensus.
The quality of the available evidence was assessed using the
framework of the Grading of Recommendations Assessment,
Development and Evaluation Working Group (Supplementary
Table 2), where the quality of each included study was graded
on a 4 point scale from very low to high.19Evidence Synthesis
Following the systematic search and post-hoc analysis, all end-
points for which sufﬁcient evidence was identiﬁed for the com-
parison of mirabegron to onabotulinumtoxinA were compared
via a NMA. All networks differentiated between placebo injec-
tion, placebo mix, and placebo oral to account for differences in
placebo response across the different forms of placebo. Placebo
mix refers to “double dummy” designs where both oral and injec-
tion placebos were administered to all individuals in the placebo
trial arm, oral placebo was administered to individuals receiving
an injection intervention, and injection placebo was adminis-
tered to individuals receiving an oral intervention, in order to
maintain blinding.12,13 For endpoints for which results did notUROLOGY 127, 2019
vary notably across different placebo responses, a sensitivity anal-
ysis was conducted in which the different placebo forms were
pooled into a common placebo, simplifying the network and
reducing the number of parameters being estimated.
Statistical Analysis. This NMA was conducted using a Bayesian
approach, and followed recommendations for the conduct of evi-
dence synthesis set forth by National Institute for Health and
Care Excellence Decision Support Unit guidance docu-
ments.20,21 Continuous endpoints were modeled with a normal
likelihood and identity link function. Binary endpoints were
modeled with a binomial likelihood and logit link function, and
results presented on the odds ratio (OR) scale.
Mirabegron 50 mg was the intervention of interest; to ensure
direct comparability of results across NMAs, mirabegron was set
as the reference treatment within the analyses (see Fig. 1). Mar-
kov chain Monte Carlo simulations (100,000 iterations; 20,000
as burn-in) with Gibbs sampling were run to estimate relative
treatment effects. Point estimates were obtained by averaging
the estimates across all retained iterations, with the credible
interval (CrI) deﬁned by the 2.5th and 97.5th percentiles. For
binary endpoints the log-OR scale was used. Vague priors were
set for all trial baselines and between-study standard deviation
(SD). Both ﬁxed effect (FE) and random effects (RE) models
were run, and the RE model was preferred a priori given the
expectation of residual heterogeneity between studies. The FE
model was selected over the RE model only if the deviance infor-
mation criterion indicated that the former provided better model
ﬁt, or the posterior distribution of the SD parameter was not well
estimated in the RE model.Figure 1. Network meta-analysis network structure
M, mirabegron; ONA, onabotulinumtoxinA; OXY, oxybutynin
mix (injection + oral); S, solifenacin; TOL, tolterodine.
UROLOGY 127, 2019Given the Bayesian approach taken (which precludes use of
frequentist statistical signiﬁcance measures), the magnitude of
the beneﬁt was described based on the proportion of the CrI that
fell on the point estimate side of equivalence: mild if the per-
centage of the CrI was <90%, moderate if the percentage of the
CrI was ≥90%, and strong if the CrI was entirely on one side of
equivalence.Assessment of Inconsistency. Consistent with good practice,22
studies identiﬁed in the systematic search were assessed for
homogeneity and consistency.
Additional details on the antimuscarinics used to develop the
network and on the assessment of inconsistency are available
upon request.RESULTS
Characteristics of Included Studies
In the systematic search, 2858 abstracts were identiﬁed, of which
280 were eligible for full-text review. Fifteen articles, represent-
ing 13 studies, were eligible for data extraction and synthesis
(Fig. 2).8,11-17,23-35 The studies by Everaert et al.12 and Hersc-
horn et al.13 reported different endpoints from a single trial;36
the 2 publications were therefore pooled and counted as a single
study. Similarly, the results of Dmochowski et al.25 were pooled
with those reported in Rovner et al.33 as the 2 publications
described a single trial. The article by Khullar, 2013,26 compar-
ing placebo oral, mirabegron 50 mg and tolterodine 4 mg, was
included in the systematic search. However, as this study was; PBI, placebo injection; PBO, placebo oral; PBM, placebo
3
Abstracts identified
EMBASE & Medline = 2,858
PubMed = 144
Total 3,002
Articles for full text review
280
Exclusions, abstract review
Duplicate = 178
Study design = 1,945
Population = 437
Intervention = 124
Outcomes = 38
Other = 0
Total = 2,722
Exclusions, hand searching 
reference lists, and 
conference proceedings
Duplicate = 35
Study design = 48
Population = 1
Intervention = 4
Outcomes = 13
Other = 0
Total = 101
Additional inclusions
6
Additional inclusions
0
Articles for inclusion
20
Inclusions, post-hoc 
analysis
Articles = 6
Total = 6
Exclusions, full text review
Duplicate = 35
Study design = 46
Population = 168
Intervention = 8
Outcomes = 4
Other = 5
Total = 266
Figure 2. PRISMA flow diagram for study inclusion in the
network meta-analysis.included in the pooled analysis reported by Nitti and Khullar,
2013,27 it was excluded from analysis applicable in the NMA to
avoid double counting.
An additional 6 mirabegron studies were included in the post-
hoc analysis.8,11,15,16,34,35 In the ﬁnal analysis, 10 studies that
assessed mirabegron and 6 that assessed onabotulinumtoxinA
were included; none of these directly compared mirabegron with
onabotulinumtoxinA. Additionally, two that assessed tolterodine
and one that assessed solifenacin were included. The full NMA
network structure based on all identiﬁed evidence is presented in
Figure 1, using mirabegron 50 mg as the reference category.Patient Characteristics
Baseline patient characteristics were inconsistently reported
across the included studies. Among the included studies, the
number of patients ranged from 21 to 1887. Across both mirabe-
gron and onabotulinumtoxinA studies, patients were predomi-
nantly female; the proportion of female patients ranged from459.8% to 90.2% in mirabegron study arms and 80.0% to 93.1%
in onabotulinumtoxinA study arms. The proportion of patients
who were ≥65 years of age varied between the 2 treatment
groups; across mirabegron study arms, the proportion of patients
aged ≥65 years ranged from 17.1% to 100.0%, compared to
42.6% to 53.1% among patients in onabotulinumtoxinA study
arms. Type of OAB (ie urge urinary incontinence, frequency,
and mixed) was not reported across onabotulinumtoxinA trials.
Across mirabegron studies, urge urinary incontinence was the
most common OAB type reported, making up to 33.3% to
61.0% of patients with OAB.Network Meta-analysis
Sufﬁcient and consistent evidence was available to analyze the
following efﬁcacy and safety endpoints: total micturitions per
24-hours, incontinence episodes per 24-hours, nocturia episodes
per 24-hours, patients with UTIs, treatment-emergent adverse
events (AEs), treatment-emergent severe AEs, AE-related study
discontinuations, overall study discontinuations and voiding dif-
ﬁculty due to dysuria. Due to a lack of sufﬁcient evidence to
inform the comparison between mirabegron and onabotulinum-
toxinA, daytime micturitions per 24-hours, volume voided per
micturition, urinary retention, urgency episodes per 24-hours,
and patients with high blood pressure were excluded.Efficacy
Total Micturitions per 24-Hours. A total of 17 studies8,11-17,23-
30,32-35 contributed evidence on the number of total micturitions
per 24-hours. Estimates of treatment effects for the RE model
identiﬁed a greater reduction in the total number of micturitions
for onabotulinumtoxinA relative to mirabegron 50 mg (0.43
fewer micturitions) although the evidence was not strong in
favor of onabotulinumtoxinA (CrI: ¡1.22, 0.37) (Fig. 3). As
there was no evidence of different placebo response in this net-
work, placebo forms were subsequently pooled into a common
placebo in sensitivity analysis. In this network, onabotulinum-
toxinA was strongly associated with greater efﬁcacy for reducing
the number of micturitions relative to mirabegron 50 mg, with
an estimated 0.64 fewer micturitions (CrI: ¡1.01, ¡0.26).Incontinence Episodes per 24-Hours. Eighteen studies8,11-17,23-
27,29-35 contributed evidence on the number of incontinence
episodes per 24-hours. Estimates of treatment effects for the RE
model identiﬁed that onabotulinumtoxinA was weakly associ-
ated with a reduction in the total number of incontinence epi-
sodes relative to mirabegron 50 mg (¡0.46 fewer incontinence
episodes; CrI: ¡1.46, 0.53) (Fig. 3). The efﬁcacy of mirabegron
50 mg relative to placebo varied depending on placebo type. As
such, assuming a common placebo for the endpoint of inconti-
nence episodes was not plausible and was not considered in sen-
sitivity analysis.Nocturia Episodes per 24-Hours. A total of 10 studies8,11-13,15-
17,29,30,34,35 contributed evidence on the number of nocturia epi-
sodes per 24 hours. Estimates of treatment effects for the RE
model identiﬁed that mirabegron 50 mg was estimated to be sim-
ilarly efﬁcacious to onabotulinumtoxinA at reducing nocturia
episodes (mean difference = 0.03, CrI: ¡0.30, 0.38) (Fig. 3). As
there was no evidence of different placebo response under this
network, placebos were again pooled into a common placebo in
sensitivity analysis. In this analysis, mirabegron 50 mg wasUROLOGY 127, 2019
Figure 3. Summary of efficacy and safety results for mirabegron 50 mg compared with onabotulinumtoxinA.
CrI, credible interval; OR, odds ratio; SA, sensitivity analysis.estimated to be similarly efﬁcacious as onabotulinumtoxinA at
reducing nocturia episodes.Safety
Urinary Tract Infections. Estimates of treatment effects on
UTIs were informed by 14 studies.8,11-13,15-17,23-25,29,30,32-35 In
the RE model, onabotulinumtoxinA was associated with greater
odds of UTI relative to mirabegron 50 mg (OR = 2.97, CrI: 0.87,
10.21) (Fig. 3), although the strength of the evidence was mod-
erate, as the CrI crossed 1, and it was associated with consider-
able uncertainty.
No evidence of different placebo response was found for this
network, as such, placebos were pooled into a common placebo
in sensitivity analysis. For this analysis, there was strong evi-
dence of threefold higher odds of a patient experiencing a UTI
when receiving onabotulinumtoxinA relative to mirabegron
50 mg (CrI: 1.61, 5.88).Treatment-Emergent Adverse Events (AEs). Fourteen stud-
ies8,11-17,23,25,29,30,32-35 contributed evidence on the number of
patients with treatment-emergent AEs. The NMA suggested
that the odds of a patient experiencing a treatment-emergent
AE were 1.62 times higher for onabotulinumtoxinA relative to
mirabegron 50 mg; however, the evidence was not strong (CrI:
0.56, 4.53) (Fig. 3). There was some variation on the relative
risk of treatment-emergent AEs depending on the type of pla-
cebo, so a network assuming a common placebo was not consid-
ered for this endpoint.Urinary Retention. Cases of urinary retention were reported in
the onabotulinumtoxinA studies, with between 6 and 16 cases
reported across studies. However, absence of any urinary reten-
tion events for mirabegron and antimuscarinics did not allow for
establishing relative safety of mirabegron versus onabotulinum-
toxinA (ie, indeterminate OR) within the context of the NMA.
As such, urinary retention could not be formally assessed.UROLOGY 127, 2019Additional Safety Endpoints. Overall, large CrIs were obtained
for both the FE and RE models conducted for treatment-emer-
gent severe AEs, AE-related study discontinuations, all-cause
study discontinuations and voiding difﬁculty due to dysuria,
which yielded uninformative results for these models. Details on
these endpoints can be found in Supplementary Materials:
Safety Endpoints.Assessment of Inconsistency. There was no evidence of incon-
sistency for any endpoint. Results from the assessment of incon-
sistency are available upon request.DISCUSSION
The present study characterized the efﬁcacy and safety of
mirabegron 50 mg relative to onabotulinumtoxinA 100 U,
in patients with OAB previously treated with antimuscar-
inics, in the absence of direct comparative evidence. In
clinical practice, mirabegron and onabotulinumtoxinA are
typically reserved for patients who have failed prior treat-
ments with antimuscarinics.4 As such, a study that thor-
oughly compared the efﬁcacy and safety of these therapies
is warranted, so that well-informed decisions can be made
in clinical practice when selecting subsequent therapy after
failure with antimuscarinics.
Results from the NMA demonstrated that onabotuli-
numtoxinA was strongly associated with a reduction on
the number of micturitions in a 24-hour period (0.64
fewer micturitions; CrI: ¡1.01, ¡0.26) relative to mirabe-
gron, and weakly associated with reducing the number of
incontinence episodes (¡0.46; CrI: ¡1.46, 0.53). There
was no evidence of differences in efﬁcacy with either
agent for the management of nocturia episodes. With
respect to safety, onabotulinumtoxinA was strongly asso-
ciated with threefold greater odds of UTIs relative to mir-
abegron (OR = 3.10, CrI: 1.61, 5.88). This analysis did5
not provide speciﬁc evidence of a different safety proﬁle
between the 2 agents for any other safety endpoints inves-
tigated in the NMA. Notably, however, while no urinary
retention events were reported across the mirabegron
studies, this endpoint was reported in 4 of the 6 onabotuli-
numtoxinA studies, with the number of events across
studies ranging from 6 to 16, indicating that this is an
important safety consideration for onabotulinumtoxinA.
The ﬁndings of this study are similar to those reported
in recently published NMAs by Freemantle et al.9 and
Drake et al.10 although the efﬁcacy beneﬁts associated
with onabotulinumtoxinA were less pronounced, while
addressing some key limitations of these studies. Due to
the high placebo response reported in OAB trials,37,38 an
important strength of the current study was that the
potential for differences in placebo response was exam-
ined and accounted for as applicable, thereby minimizing
any bias that may have been introduced into the compari-
son of interest via effect modiﬁcation of treatment efﬁcacy
by patient characteristics or differences in placebo
response. For each endpoint-speciﬁc network it was
assumed a priori that different placebo forms (and associ-
ated difference in frequency) were susceptible to different
placebo responses, by including different placebo forms as
different nodes in the network of evidence. The decision
to pool placebos was made only if there was no evidence
of different placebo responses (deﬁned by substantial over-
lap of the CrIs associated to the different placebo forms
relative to the reference treatment), and as long as there
was enough precision to estimate the relative difference.
There was no evidence of different placebo response in
the networks of evidence for total micturitions, nocturia
episodes, and UTIs. Overall, pooling placebos resulted in
narrower CrIs around effect estimates. The evidence sug-
gested a potential for differences in placebo response
in the network of urinary incontinence. As such,
the network with separate placebos was retained for
this endpoint.
Another strength of this study was the focus on a treat-
ment-experienced patient population, which led to a
more homogeneous evidence base across studies with
respect to disease severity compared to prior NMAs. Free-
mantle et al.9 and Drake et al.10 included statistical adjust-
ments for imbalances on baseline disease severity via
network meta-regression but given substantial differences
in treatment history and disease severity between patients
enrolled in onabotulinumtoxinA trials relative to mirabe-
gron trials, the data may have been insufﬁcient for appro-
priately adjusting for those imbalances. Speciﬁcally,
Freemantle et al.9 conducted network meta-regression
using aggregate data, as well as individual patient-level
data (IPD) from 2 onabotulinumtoxinA studies. The
authors acknowledged that the aggregate data were insufﬁ-
cient to accurately estimate the effect of differing baseline
disease severity on endpoints and supplemented these
with analyses relying on IPD which lacked evidence spe-
ciﬁc to mirabegron. This limitation of the IPD required
assuming the same impact of symptom severity on6endpoints in both mirabegron and onabotulinumtoxinA
studies. Although narrowing the focus in the deﬁnition of
patient population leads to fewer studies informing the
analyses, it does not necessarily reduce the precision in
generated estimates, as having a heterogeneous mix of
patients (ie, treatment-na€ıve and treatment-experienced
patients all with varying levels of symptom severity) can
lead to considerable between-study variance. Overall,
only mild heterogeneity was present across endpoints
(as indicated by small between-study SDs and tight associ-
ated CrIs). For some of the safety endpoints, large
between-study SDs were likely due to a sparse evidence
base, rather than heterogeneity in the evidence base.
Although the efﬁcacy results generated by this study are
in line with the results reported by Freemantle et al.9 and
Drake et al.,10 the magnitude of the estimated effects was
lower in the present study. This may be due to having a
more homogeneous evidence base. The quality of the
available evidence was assessed using the framework of
the Grading of Recommendations Assessment, Develop-
ment and Evaluation Working Group (Supplementary
Table 2). All identiﬁed studies were determined to be of
moderate or high quality.39
Lastly, this study provides a comprehensive overview of
the comparability of mirabegron versus onabotulinumtox-
inA, with 7 additional studies contributing to the network
of evidence. Both efﬁcacy and safety were investigated in
this analysis, while the NMAs by Freemantle et al.9 and
Drake et al.10 did not report on any safety endpoint, pro-
viding only a partial overview on the comparability of the
2 regimens. Overall, onabotulinumtoxinA was strongly
associated with a threefold greater risk of UTIs relative to
mirabegron. While the analysis did not provide evidence
of a different safety proﬁle between the 2 agents for any
other safety endpoints investigated in the NMA, it should
be noted that the proportion of patients experiencing uri-
nary retention ranged from 5.4% to 10.9% across onabo-
tulinumtoxinA trials and was 0% across mirabegron trials.
As such, although urinary retention was reported in
enough studies to generate a connected network, as none
of the patients treated with mirabegron experienced uri-
nary retention, a formal quantitative assessment of rela-
tive safety of mirabegron versus onabotulinumtoxinA
could not be performed.
Limitations
There are limitations inherent to NMAs that warrant
mention. This NMA incorporated evidence from the
subset of eligible treatment-experienced patients in mir-
abegron studies where the overall population did not
meet the inclusion criteria of the systematic search.
While these additional data provided important evi-
dence in the comparisons of interest, conducting post-
hoc analyses restricts the analysis to only a subset of the
overall study population, limiting power and excluding
a portion of the mirabegron evidence base. Baseline
characteristics were compared between the full study
population and the subset of treatment-experiencedUROLOGY 127, 2019
patients (data available upon request). Overall, baseline
characteristics aligned with those reported in the origi-
nal studies, suggesting that limiting the population to
treatment-experienced patients did not induce other
major differences to population makeup. While all
NMAs are limited by the heterogeneity of the patient
characteristics, the post-hoc analysis was undertaken to
create a more homogeneous patient population than
previous NMAs conducted in patients with OAB.
Potential residual heterogeneity includes the fact that
while patients in the mirabegron and antimuscarinics
trials may have had prior experience with antimuscar-
inics, some may not have failed treatment; in contrast,
those in onabotulinumtoxinA studies most likely had
already failed several other treatments. Given the lim-
ited data available, it was not possible to adjust for these
potential differences in prior treatment exposure.CONCLUSION
This study provides a comprehensive overview of the
available evidence comparing mirabegron 50 mg with
onabotulinumtoxinA 100 U with respect to efﬁcacy and
safety. Evidence suggests that although onabotulinum-
toxinA is more efﬁcacious at reducing the number of
daily micturitions in a treatment-experienced OAB pop-
ulation, relative to mirabegron, it is also associated with
an estimated threefold greater risk of UTIs. Further-
more, although the relative safety of urinary retention
between onabotulinumtoxinA and mirabegron could
not be quantiﬁed due to statistical limitation, it was
identiﬁed as a safety outcome in onabotulinumtoxinA
studies. These results suggest that the efﬁcacy beneﬁts
associated with onabotulinumtoxinA among treatment-
experienced patients may be less pronounced than pre-
viously reported among mixed populations with OAB.
In the absence of head-to-head comparisons, this study
helps to inform the risk-beneﬁt of mirabegron and ona-
botulinumtoxinA for treatment-experienced patients
with OAB, that will assist clinicians and patients with
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